Entities

François Santi is named as Partner in the still-published legacy Anaxago Capital directory. This affiliation is retained as a dated legacy disclosure; the current Ambra directory does not corroborate continued employment. No exact employment start or end day is published.

Jeroen van der Pol is publicly named by ALS Investment Fund as chief financial officer. The current official roster identifies this professional affiliation and publishes an authentic named portrait. ALS Investment Fund is a Netherlands-based neurodegeneration investment platform managed by SUNU Ventures B.V.; its investment, scientific, advisory and operational functions are distinct. Further career history and an exact appointment date are not supplied by this roster.

Michelle Meijerink is publicly named by ALS Investment Fund as compliance. The current official roster identifies this professional affiliation and publishes an authentic named portrait. ALS Investment Fund is a Netherlands-based neurodegeneration investment platform managed by SUNU Ventures B.V.; its investment, scientific, advisory and operational functions are distinct. Further career history and an exact appointment date are not supplied by this roster.

Nancy de Ruiter is publicly named by ALS Investment Fund as chair — advisory committee. The current official roster identifies this professional affiliation and publishes an authentic named portrait. ALS Investment Fund is a Netherlands-based neurodegeneration investment platform managed by SUNU Ventures B.V.; its investment, scientific, advisory and operational functions are distinct. Further career history and an exact appointment date are not supplied by this roster.

Olivier Tak is publicly named by ALS Investment Fund as science and due diligence. The current official roster identifies this professional affiliation and publishes an authentic named portrait. ALS Investment Fund is a Netherlands-based neurodegeneration investment platform managed by SUNU Ventures B.V.; its investment, scientific, advisory and operational functions are distinct. Further career history and an exact appointment date are not supplied by this roster.

Siya Chandrie is publicly named by ALS Investment Fund as investor relations. The current official roster identifies this professional affiliation and publishes an authentic named portrait. ALS Investment Fund is a Netherlands-based neurodegeneration investment platform managed by SUNU Ventures B.V.; its investment, scientific, advisory and operational functions are distinct. Further career history and an exact appointment date are not supplied by this roster.

Craig Boyce is a managing partner of ALS Investment Fund. Its December 2025 announcement describes more than 25 years of private-equity experience, including a former managing-director role at Bain Capital, and a longstanding commitment to ALS academic research and patient services.

Rist Brouwer is publicly named by ALS Investment Fund as advisor — investment committee. The current official roster identifies this professional affiliation and publishes an authentic named portrait. ALS Investment Fund is a Netherlands-based neurodegeneration investment platform managed by SUNU Ventures B.V.; its investment, scientific, advisory and operational functions are distinct. Further career history and an exact appointment date are not supplied by this roster.

Gladys Nunez is currently listed by Amgen Business Development as Executive Director, Ventures. Portfolio company Casma describes responsibility for venture diligence, deal execution and portfolio board-observer work, and a career at Amgen beginning in1997, spanning laboratory research and business development. She previously conducted research at AstraZeneca and Amgen. Her published education comprises an MSc in biochemical pharmacology from Southampton and a BSc from Marist College. Her current own corporate title is used instead of older principal/director titles.

Jacob Tutor is publicly listed as Manager in the Amgen Ventures section of Amgen Business Development’s current team directory. The venture team invests in emerging healthcare, biotechnology and digital-technology companies and provides access to Amgen scientific and development expertise. His published corporate affiliation is distinguished from personal investing; education, earlier career and appointment date are not disclosed in the reviewed primary card.

Joshua Crapser, PhD, is publicly listed by Amgen Business Development as Manager in the Amgen Ventures team. The corporate venture function identifies and supports healthcare and tech-bio innovators through equity capital and access to Amgen drug-development capabilities. His professional affiliation and doctoral designation are sourced from the current own named team card; prior employers, doctorate institution and personal investment activity are not established by that directory.

Rachna Khosla joined Amgen in2013 and became Senior Vice President of Business Development in September2021. Her corporate remit expressly includes Amgen Ventures alongside M&A, licensing, search/evaluation and alliance management. She previously held corporate-development roles at Amgen and healthcare M&A roles at Lazard, Credit Suisse, Sanofi/Aventis, J.P. Morgan and Salomon Brothers. She holds a BA from Barnard College and an MBA from Columbia Business School. The venture oversight affiliation is distinguished from a dedicated venture investing title.

Christophe Pieri is published as Impact Investing Portfolio Manager / AxClimat Fund Manager by Ambra Capital. The own fund article identifies him as manager of AxClimat I, focused on European decarbonisation fund investments.

Alexandre Pelletier is published as Venture Partner — CapHorn venture brand by the CapHorn venture-capital brand. He joined CapHorn in2017 following more than15 years of international operating experience, including Microsoft and Tata Communications.

CMS Medical Venture Investment (HK) Limited is the Hong Kong corporate investment-holding vehicle named as an actual shareholder and investor in healthcare and life-science companies. It is distinct from Cayman-incorporated China Medical System Holdings Limited, the group’s operating and listed parent, and from similarly named BVI and Singapore companies. A2019 joint SEC Schedule13D and2022 Gelesis Schedule13G confirm the Hong Kong vehicle as a wholly owned CMS subsidiary and direct holder of investments; indirect parent beneficial ownership is not a second paid check. The 2019 filing identifies its principal business address as Unit2106,21/F, IslandPlaceTower,510King’sRoad,NorthPoint,HongKong. Its published subsidiary governance comprises two named directors, LamKong and HuaizhengPeng, historically confirmed2019; Peng additionally signs its2022 filing as director. The current CMS group biographies independently identify Lam as group founder/chairman/chief executive and Peng as chief business officer, but those current parent positions are not asserted as new current subsidiary operating roles. This record uses authentic CMS group branding with explicit parent-brand qualification because no independently branded subsidiary logo or dedicated subsidiary site was located. A&B(HK)CompanyLimited and its BVI parent are separate investment entities associated with LamKong; they are not CMSHK aliases or automatically wholly owned CMS subsidiaries. In2019 CMSHK and A&BHK each independently paid approximately GBP4M for Midatech shares/warrants from their own working capital. The parent and Lam made no direct purchases in that transaction, and commercial licensing milestones are not equity cash. Midatech and Gelesis are historical portfolio evidence; historical holdings do not prove current ownership or a new financing. Actual2018 Acticor SeriesB participation is sourced by issuer release and linked separately, with individual check unknown. Acticor entered judicial liquidation in January2025; no clinical efficacy or current operation is implied by this historical investment. Corporate paid-up share capital, group AUM and partner license capacity are not LP fund closes. No pooled external fund vehicles, independent subsidiary staff directory or exact current subsidiary directors’ tenure were disclosed in the reviewed sources.

Huaizheng Peng, styled Peng Huaizheng in the CMS directory, is China Medical System’s published chief business officer. After serving as an independent non-executive director from May2010 to October2013, he continued working with the group. His prior career includes life-science investment roles in UK and Canadian financial firms. He earned clinical-medicine degrees at Hunan Medical College in1984 and1989 and a molecular-pathology doctorate at UniversityCollegeLondon in1998, and taught histopathology there. SEC2019 separately names him director of the HongKong investment vehicle and chief executive of distinct A&BHK; he signs CMSHK’s2022 Gelesis filing as director. Those dated subsidiary roles are not inferred from his present parent-group title.

Lam Kong founded China Medical System and is identified in its own current directory as chairman, chief executive and president. He directs the group’s development strategy and has a medical and pharmaceutical-commercial background. He studied clinical medicine at Zhanjiang Medical College, graduating in1986. SEC2019 identifies him separately as director of CMS Medical Venture Investment(HK), and sole director/indirect owner of the distinct A&B corporate investment entities. Subsidiary roles are source-qualified historical; no personal investment check is inferred from control of corporate buyers.

Flora Coppolani is published as Managing Partner — CapHorn venture brand by the CapHorn venture-capital brand. She joined CapHorn in2022 following experience at Bpifrance and Rocket Internet and manages its venture team.

Pierre Lainé is published as Director of Venture Capital Portfolio by Ambra Capital. The caption supports the stated institutional responsibility; no unverified educational history, exact tenure day or individual investment is inferred.

Olivier Budin is published as Asset Manager by Ambra Capital. The caption supports the stated institutional responsibility; no unverified educational history, exact tenure day or individual investment is inferred.

Caroline Seillier is published as Senior Portfolio Manager by Ambra Capital. The caption supports the stated institutional responsibility; no unverified educational history, exact tenure day or individual investment is inferred.

Fabien Krésac is published as Senior Investment Manager by Ambra Capital. The caption supports the stated institutional responsibility; no unverified educational history, exact tenure day or individual investment is inferred.

Vincent Lachene is published as Director of Development by Ambra Capital. The caption supports the stated institutional responsibility; no unverified educational history, exact tenure day or individual investment is inferred.

Deepak Asudani is a UC San Diego clinical professor and hospital-medicine physician with expertise in public health, applied genomics and medical management. gMendel announced his board appointment on May29,2023, and its2023 review described his work on health systems and US expansion. This records a historical published board affiliation; current membership is not asserted.

Ken Ndugga-Kabuye was listed in gMendel’s January2023 company presentation as US Market Advisor. This records a dated professional affiliation; continuing2026 employment is not confirmed.

Lars Staal Wegner is a physician, AI-biotechnology executive and former Evaxion CEO. gMendel announced his appointment as board chairman effective November1,2022 and included him in its January2023 presentation. Its current directory names Zoran Zdraveski as chairman, so the gMendel affiliation recorded here is historical.

Agnieszka Tymoszyk was listed in gMendel’s January2023 company presentation as Quality Assurance. This records a dated professional affiliation; continuing2026 employment is not confirmed.

Marija Andrileou was listed in gMendel’s January2023 company presentation as Marketing and Communications. This records a dated professional affiliation; continuing2026 employment is not confirmed.

Wouter Hamel was listed in gMendel’s January2023 company presentation as Advocacy and Sales Development. This records a dated professional affiliation; continuing2026 employment is not confirmed.

Dariusz Nablotczyk was listed in gMendel’s January2023 company presentation as Software Architect. This records a dated professional affiliation; continuing2026 employment is not confirmed.

Marija Chaushevska was listed in gMendel’s January2023 company presentation as AI Researcher. This records a dated professional affiliation; continuing2026 employment is not confirmed.

David Galevski was listed in gMendel’s January2023 company presentation as Data Scientist. This records a dated professional affiliation; continuing2026 employment is not confirmed.

Anne Kristine Schack was listed in gMendel’s January2023 company presentation as Genomics Researcher. This records a dated professional affiliation; continuing2026 employment is not confirmed.

Karmele Alapont Celaya was listed as a genomics researcher in gMendel’s January2023 presentation. Company-hosted2024–2025 publications bridge the shorter Karmele Alapont name to her full name. This is a dated research affiliation; continuing2026 employment is not confirmed.

Kristijan Jankoski was listed in gMendel’s January2023 company presentation as Senior Data Scientist. This records a dated professional affiliation; continuing2026 employment is not confirmed.

Aleksandar Nikov was listed in gMendel’s January2023 company presentation as Head of AI. This records a dated professional affiliation; continuing2026 employment is not confirmed.

Tomas Puk was listed in gMendel’s January2023 company presentation as Head of Quality by Design. This records a dated professional affiliation; continuing2026 employment is not confirmed.

Hanna Pyokari is a gMendel co-founder identified in its January2023 presentation and2023 review. The company announced her board appointment effective November1,2022. She holds economics and business-administration and CEMS qualifications, with experience in pharmaceuticals and financial planning. The signed2022 annual report uses her full name Hanna Marjaana Pyökäri. This board affiliation is historical; continuing2026 membership is not asserted.

Johan Leonhard is gMendel’s legal adviser and an attorney and partner at Nyborg & Rørdam. His published background covers intellectual property, data protection and commercial and company law, including earlier in-house counsel and data-protection responsibilities.

Lukasz Krych is gMendel’s genomic adviser and an associate professor in food science at the University of Copenhagen. His research includes molecular assays, sequencing protocols and high-throughput quantitative PCR.

Zoran Zdraveski chairs gMendel’s board. A biochemistry PhD with chemistry and law qualifications, he is a biopharmaceutical legal and intellectual-property executive at TScan Therapeutics, with earlier Magenta and Epizyme experience. The company announced his board appointment in May2023; its January2023 presentation records an earlier strategic-adviser capacity.

Antonina Burlachenko leads regulatory and quality assurance at gMendel, under the published title CRQA. She has an electronics and acoustics master’s degree and more than a decade of regulatory and quality experience in diagnostics, overseeing compliance and quality-management work.

Dimitrios Kyriakidis is gMendel’s Chief Commercial Officer. His published biography describes sales and marketing qualifications and medical-device commercial experience at Stryker and Johnson & Johnson. The earlier company presentation lists him as Dimitri Kyriakidis in advocacy and sales development.

Gjorgji Madjarov is gMendel’s Chief Artificial Intelligence Officer and a professor at Ss. Cyril and Methodius University. His background is in computer science, information technology, advanced AI and machine-learning algorithms. The January2023 presentation records an earlier AI-adviser capacity.

Carmen Garrido Navas is gMendel’s Chief Scientific Officer. A genetics PhD, her published biography describes research supervision and teaching at the University of Granada. The earlier company presentation lists her clinical-evaluation responsibilities.

Zoran Velkoski is gMendel’s CTO and co-founder. He holds qualifications in embedded systems and business administration and has extensive entrepreneurship and product-development experience in deep technology. The current company directory and signed annual report confirm Velkoski; Velkovski appears only in the original portrait filename.

gMendel is a Copenhagen genetic-diagnostics and medical-software company, legally gMendel ApS, Danish CVR41505524. Founded in2020 by Chris (registered Christos) Kyriakidis, Zoran Velkoski and Hanna Pyokari, it develops Phivea and Test-SCAN software combining genomic sequencing, AI and machine learning to support screening and diagnosis of genetic and rare disorders, including neurological conditions. Its current directory identifies nine executives and advisers; earlier2022–2023 professional and board affiliations are separately dated. The company reports Danish registration and CE marking of Phivea v1 under the former EU IVDD; this audit independently verified its legal company in the Danish Medicines Agency register, not an individual product certificate or FDA approval. Its genuine LRQA ISO13485:2016 certificate, issued June11,2026 and expiring June10,2029, covers design, development and service of in-vitro-diagnostic medical-device software: a quality-system certification, not a treatment approval or independent proof of diagnostic performance. Business roadmaps and expansion pilots are distinguished from clinical-trial phases and commercial revenue. A completed DKK9M seed round announced April16,2026 was led by Metavallon VC. Earlier disclosures identify approximate2022 angel funding,2023 CVX-network backing and limited2025 financing from iFutura and Quaternity; amounts, exact payment dates and underlying instruments are not invented. Innovation Fund Denmark awarded separate Innobooster2022–2023 and Eurostars2023–2025 contributions, with project budgets distinct from support and paid cash unpublished. The issuer’s May2022 EUR200K grant report is preserved alongside the grantor’s DKK1,320,988 programme figure without assumed currency equivalence or an additional duplicate award. Cumulative EUR1.8M pre-seed reporting, funding targets, loan balances and applications are not represented as additional completed cash rounds.

Chris Kyriakidis is gMendel’s CEO and co-founder. He holds a doctorate, a master’s in physics and an MBA, with earlier international healthcare experience at Novo Nordisk and GN. The signed company annual report and LRQA certificate identify the same executive as Christos Kyriakidis. Quaternity ApS’s signed2025 annual statements also identify him under his legal name Christos Kyriakidis as its director; the June25,2026 signature is evidence of that documented governance position, not an inferred personal financing allocation.

Aja Guldhammer Henderson is published by Antler as Nordics Operating Partner.

Anna Munthe-Kaas is published by Antler as Associate Partner, Oslo.

Balder Eklöf Eira is published by Antler as Investment Team.

Clara Reich is published by Antler as Investment Team.

Gill Hauzmann is published by Antler as Investment Team.

Helen Park is published by Antler as Director, Platform.

Kaila Lim is published by Antler as Director, Community.

Leo Philippsthal is published by Antler as Platform & Community.

Markus Lukk is published by Antler as Investment Team.

McKenzie Hagan is published by Antler as Senior Manager, Scouting.

Rahim Shah is published by Antler as Controller.

Sam Blumenthal is published by Antler as Principal.

Aaron Sotunde-Adesina is published by Antler as Associate.

Adam Jaffer is published by Antler as Advisor.

Afroz Dairkee is published by Antler as Director.

Alannah Roche is published by Antler as Investment Associate.

Alex Wright is published by Antler as Principal.

Amer Mkhalalati is published by Antler as Venture Partner.

Ammar Zaidi is published by Antler as Senior Finance Associate.

Anshul Tibrewala is published by Antler as Head of Marketing.

Ashish Jain is published by Antler as Venture Partner.

Ashish Patel is published by Antler as Fractional CTO.

Audrey Gunawan is published by Antler as Senior Finance Associate.

Baghdad Gherras is published by Antler as Venture Partner.

Bazil Azmil is published by Antler as Principal.

Beatriz Montiani is published by Antler as Investment Director.

Beau Seil is published by Antler as Venture Partner.

Behdad Shahsavari is published by Antler as Venture Partner.

Caroline Healey is published by Antler as Senior Principal.

Cash Allred is published by Antler as Senior Principal.

Daniel Chenube is published by Antler as Associate.

Daphne McLarty is published by Antler as Principal.

Darren Murphy is published by Antler as Vice President.

Devna Kashyap is published by Antler as Senior Portfolio Manager.

Doori Jung is published by Antler as Finance Manager.

Dravisha Katoch is published by Antler as Associate.

Edward Goff is published by Antler as Venture Partner.

Felipe Guedes is published by Antler as Marketing Content Producer.

Florian Geier is published by Antler as Senior Director.

Florian Jansen is published by Antler as Venture Partner.

Georg Hartmann is published by Antler as Venture Partner.

Gowri Shankar is published by Antler as Associate Partner.

Ha Phan is published by Antler as Growth & Marketing Associate Director.

Hailey Hyewon Song is published by Antler as Program Manager.

Hala Ebrahim is published by Antler as Associate Partner.

Halah Al Jubeir is published by Antler as Managing Director (KSA).

Heechan Kim is published by Antler as Senior FX Manager.

Himank Amar is published by Antler as Analyst.

Ifelayomi Odubawo is published by Antler as Finance Associate.

Imogen Jones is published by Antler as Scouting Manager.

Jake O'Shea is published by Antler as Principal.

Jasnoor Gill is published by Antler as Director.

Jerry Gamez is published by Antler as Venture Partner.

João Braga is published by Antler as Fund Ops Analyst.

John Mady is published by Antler as Venture Partner.

Jonathan Labin is published by Antler as Venture Partner.

Jordan Fisher is published by Antler as Venture Partner.

Juan Galan is published by Antler as Venture Partner.

Juyeop Kwon is published by Antler as Senior Analyst.

Kaito Nozawa is published by Antler as Program Manager.

Karan Teckchandani is published by Antler as Investment Manager.

Keith Lim is published by Antler as Finance Director.

‍Kosen Kenta is published by Antler as Investment Principal.

Leila Oliveira is published by Antler as Senior Investment Manager.

Leila Trulsen is published by Antler as Investment Manager.

Lisa Potocsnak is published by Antler as Partner, Finance & Operations.

Lorenzo Peracchione is published by Antler as Venture Partner.

Malik Alyousef is published by Antler as Venture Partner.

Manav Daryanani is published by Antler as Venture Partner.

Marc Weill is published by Antler as Venture Partner.

Maximilian Plank is published by Antler as Venture Partner.

Min Tan is published by Antler as Finance, Director.

Minos Minas is published by Antler as Gaming Lead.

Mo Ghahroudi is published by Antler as Venture Partner.

Mohamed Hamza is published by Antler as Director, Investments.

Najla Zamri is published by Antler as Investment Director.

Nikolaus Föbus is published by Antler as Venture Partner.

Olivia Irish is published by Antler as Scouting Associate.

Omar Chihane is published by Antler as Venture Partner.

Pulkit Srivastava is published by Antler as Venture Partner.

Rachel Guest is published by Antler as Senior Manager, Program.

Raghav Chopra is published by Antler as Associate.

Raghav Goyal is published by Antler as Manager.

Rakesh Sah is published by Antler as Finance Manager.

Rana Taher is published by Antler as Investment Associate.

Renu Halepaty is published by Antler as Executive Assistant.

Richard Baillie is published by Antler as Principal.

Rio Hodges is published by Antler as Associate Partner.

Roy Junyoung Jang is published by Antler as Associate Director.

Saim Riaz is published by Antler as Investment Analyst.

Samuel Barbu is published by Antler as Finance Director.

Sankalp Sharma is published by Antler as Manager.

Sarah Finegan is published by Antler as Associate Partner.

Satomi Hoshi is published by Antler as Startup Scouting Manager.

Sebastien Wakim is published by Antler as Venture Partner.

Soyeon Kim is published by Antler as Marketing Analyst.

Stefan Knight is published by Antler as Director, Queensland.

Sujin Lee is published by Antler as Portfolio Manager.

Teddy Himler is published by Antler as Venture Partner.

Theresa Hoffmann-Mogev is published by Antler as Investment Manager.

Vignesh Prasad is published by Antler as Associate.

Wafaa Al Obaidat is published by Antler as Venture Partner.

Zahir Hassan is published by Antler as Scouting Associate.

Zahra is published by Antler as Finance Associate.

Benedikt Jaenecke is published by Antler as Investment Team.

Frederik Brandis is published by Antler as Venture Partner.

Adam French is published by Antler as Partner.

Adrian Dalton is published by Antler as Head of Compliance.

Agung Bezharie Hadinegoro is published by Antler as Partner.

Alan Poensgen is published by Antler as Partner.

Amy Zaghloul is published by Antler as Director (Middle East).

Andrea Hajdu-Howe is published by Antler as Managing Partner.

Anil Atmaramani is published by Antler as Partner.

Annabel Hodges is published by Antler as VP, Global Head of Marketing Operations.

Anthony Millet is published by Antler as Managing Partner.

Antti Tormanen formerly helped build Antler’s Helsinki office as a Partner. In his own departure announcement he said he was moving on from the operating role and would remain a Venture Partner through the end of the year; the exact end date and continuing status are unverified.

Baz Saideh is published by Antler as Partner, Business Development.

Bede Moore is published by Antler as Chief Commercial Officer.

Bernie Li is published by Antler as General Partner.

Bob Rosin is published by Antler as Managing Partner, US.

Carolina Strobel is published by Antler as Partner.

Charles Hayley-Bell is published by Antler as Partner (US).

Christoph Klink is published by Antler as Partner.

Daniel Fisher is published by Antler as VP Brand & Content. This identity is distinct from existing Adex namesakes and is matched to Antler’s own biography and identity links.

David Fischer is published by Antler as Advisory Board Member (published global advisory board). This identity is distinct from existing Adex namesakes and is matched to Antler’s own biography and identity links.

Deepak Jayaraman is published by Antler as Partner, Global Head of Business Development and Collaborations.

Desmond Poon is published by Antler as Partner (UK).

Dilan Mizrakli Landgraff is published by Antler as Co-founder & Chief Strategy Officer.

Edward Knight is published by Antler as President.

Erik Jonsson is published by Antler as Partner.

Fabian Rother is published by Antler as Director (DACH).

Fady Abdel-Nour is published by Antler as Partner.

Frank Kang is published by Antler as Associate Partner.

Frank Stevenaar is published by Antler as Chief Financial Officer.

Fridtjof Berge is published by Antler as Co-founder & Chief Business Officer.

Gabriel Jung is published by Antler as Partner.

Graeme Mather is published by Antler as Partner (Asia).

Hannah Leach is published by Antler as Partner.

Jack Davies is published by Antler as VP MARKETING & PR. Cambridge Enterprise affiliation: Jack Davies is listed by Cambridge Enterprise as Operations Associate. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

JaeHee Chang is published by Antler as Partner.

James Anderson is published by Antler as Advisory Board Member (published global advisory board).

James McClure is published by Antler as Partner.

Jed Rose is published by Antler as Partner.

Jeff Becker is published by Antler as General Partner.

Jiho Kang is published by Antler as Partner.

Job Wever is published by Antler as Investment Team.

Joie Chan is published by Antler as Manager.

Jussi Kallasvuo is published by Antler as Partner and, in its Nordics directory, General Partner in Helsinki.

Jussi Salovaara is published by Antler as Co-founder of Antler and Asia Managing Partner.

Ken Hitchner is published by Antler as Advisory Board Member (published global advisory board).

Kristian Jul Røsjø formerly worked as a Partner at Antler, helping build its Nordic investment platform and raise Nordic funds. His own departure announcement says he was leaving after eight years and that Anna Munthe-Kaas would lead the Oslo team; the exact end date is unverified.

Lavanya Indralingam is published by Antler as Partner, Head of Global Operations.

Livia Moore is published by Antler as Associate Partner.

Lola Masha is published by Antler as Partner.

Lotta Patrickson is published by Antler as Vice President, Head of People & Culture.

Magnus Grimeland is published by Antler as Founder & Chief Executive Officer.

Marcelo Ciampolini is published by Antler as Partner.

Marie Nielsen is published by Antler as Partner.

Markus Bruderer is published by Antler as Partner.

Martell Hardenberg is published by Antler as Partner.

Mathias Owing Maanum is published by Antler as Partner, Elevate.

Matt Glossop is published by Antler as Associate Partner (Canada).

Melalite Ayenew is published by Antler as Partner.

Michael Kron is published by Antler as Partner.

Michael Wiatr Aagaard is published by Antler as Partner under the name Michael J. Wiatr in its global directory and General Partner, Copenhagen in its Nordics directory. He previously worked at Boston Consulting Group and has co-founded, advised and invested in startups, including two companies that exited.

Naman Budhdeo is published by Antler as Partner Emeritus.

Nancy Zimmerman is published by Antler as Advisory Board Member (published global advisory board).

Nitin Sharma is published by Antler as Partner.

Oscar Westergård is published by Antler as Partner.

Peter Harrison is published by Antler as Advisory Board Member (published global advisory board).

Peter Schmidt is published by Antler as Director (US).

Rafael Mastrocola is published by Antler as Capital Director.

Rajiv Srivatsa is published by Antler as Partner.

Rike Döpp Bergérus is published by Antler as VP, Global Communications.

Romain (رومان) Assunção is published by Antler as Founder and Managing Partner.

Ronald Jan Schuurs is published by Antler as Partner.

Ros Bazany is published by Antler as Partner.

Roslyn Jin is published by Antler as Partner, Platform & Founder Experience.

Rufus Sorsa is published by Antler as Associate Partner.

Ryan Sommerville is published by Antler as General Partner.

Saina Chiba is published by Antler as Director (Japan).

Sandeep Casi is published by Antler as Partner, Head of Ibex Japan, Global Business Development & Collaborations.

Sarah Kimmorley is published by Antler as Vice President.

Shalaka Uchil is published by Antler as Director.

Sheila Patel is published by Antler as Co-chair.

TC Høiseth is published by Antler as Partner (Europe).

Tobias Bengtsdahl is published by Antler as Partner and, in its Nordics directory, General Partner in Stockholm.

Todd Ruppert is published by Antler as Advisory Board Member (published global advisory board).

Tore Myrholt is published by Antler as Co-chair.

Vegard Medbo is published by Antler as Co-founder & Chief Operating Officer.

Will Robinson is published by Antler as Partner, Head of Strategic Partnerships.

Winnie Khoo is published by Antler as Partner.

Yashveer Yadav is published by Antler as Associate Partner (India).

George Kroustalakis, Associate Background in AI consulting at EY, working on machine learning and data-driven solutions across industries. Passionate about scalable technologies shaping the future. BSc in Computer Science, AUEB, specializing in AI and Data Science.

Henry Umunnakwe, Platform & Ecosystem Lead Entrepreneurship ecosystem expert and founder of Athens Tech Circle. Background in Natural Gas Engineering and an MSc in Entrepreneurship from ALBA Graduate Business School, Athens.

Nancy Asimakopoulou, Associate Previously worked as Manager, handling the large-cap Private Equities at Dialectica. Loves innovative ideas that create a better future. BSc in Finance & Accounting from Athens University of Economics & Business.

Konstantinos Karvounakis, Principal, in Educational Leave Previously worked as a Business Analyst at McKinsey & Company, and has gained experience in Corporate Finance at PwC. MSc in Electrical Engineering & Computer Science from Aristotle University of Thessaloniki.

Angelos Manglis, Venture Partner Experienced consultant, engineer, and entrepreneur. Early supporter of startup financing in Greece and the region. Strategic thinker focused on exits. MSc in Technical Change and Industrial Strategy, University of Manchester.

Demetris Iacovides – Partner, Brain Gain Fund Active investor in the Greek tech ecosystem, ex-Principal at Big Pi Ventures and angel investor. Background in finance and strategy at Deloitte, PwC, and Genesis Pharma. Studied engineering, biotech, and economics at UCL, Imperial, LSE, and Grenoble EM.

George Karantonis, Partner Entrepreneur turned investor, previously co-founder of two ICT companies, also spent several years as a freelance consultant. Early participant as an operator and investor in 2 Greek NASDAQ companies. MS. in Exploration Geophysics and an MBA from ALBA.

Yorgos Mousmoulas, Partner Previously Investment Director at Attica Ventures, a Series A fund investing in IT, Telecom, Microelectronics, Automation & Robotics. Operator in technology companies and ICT strategy consultant. Electrical Engineer and INSEAD MBA.

Myrto Papathanou, Partner Finance and high tech experience in London and Athens. Loves articulate engineers and teams that can execute. Drawn to deep tech investments and industry disruptors. Multitasker, listener and connector. INSEAD MBA, Kauffman Fellow.

Neurosoft Bioelectronics is an EPFL spin-off developing soft, stretchable brain-computer interfaces that rest on the cortical surface without penetrating brain tissue. Its electrodes record and stimulate neural activity while conforming to the brain. SOFT ECoG is designed for intraoperative and short-term subdural recording and stimulation, including epilepsy surgery mapping. MINDZ is a folded electrode interface intended for deployment through a small skull opening, initially to help localize drug-resistant epileptic activity. Its development programmes also include SOFT TINNIT, an implantable closed-loop neuromodulation system for severe tinnitus, and Synapsuit, which combines neural decoding with a wearable exosuit for people with impaired arm and hand movement. The company is developing AI models for decoding cortical signals and discovering neurological biomarkers. Headquartered in Geneva with a US subsidiary in New York, it operates a Swiss medical-device production line and holds ISO 13485 certification. In May 2026 it reported testing its interfaces in ten patients across ongoing studies at UTHealth Houston and UMC Utrecht. Its brain interfaces remain investigational and are not yet available for sale in the United States or Europe.

Listed on Neurosoft Bioelectronics’ combined Board & Advisors roster. Own card context: Co-Founder at Braingrade & Aureliym, Founder at Nemotec. The directory does not distinguish a board appointment from an advisory appointment.

Listed on Neurosoft Bioelectronics’ combined Board & Advisors roster. Own card context: Former President at BioAlps Association and former CTO of Wyss Center. The directory does not distinguish a board appointment from an advisory appointment.

Listed on Neurosoft Bioelectronics’ combined Board & Advisors roster. Own card context: Professor of Neurosurgery, University Otago and Co-Founder BRAI3N-Centre for neuromodulation, Ghent. The directory does not distinguish a board appointment from an advisory appointment.

Listed on Neurosoft Bioelectronics’ combined Board & Advisors roster. Own card context: Professor of Intelligent Healthcare Technologies at Technische Universität Dresden. The directory does not distinguish a board appointment from an advisory appointment.

Listed on Neurosoft Bioelectronics’ combined Board & Advisors roster. Own card context: Medtech Startup Coach. The directory does not distinguish a board appointment from an advisory appointment.

Scientific adviser to Neurosoft Bioelectronics on neuro artificial intelligence and foundation brain modelling. Assistant professor at EPFL, where he leads the NeuroAI research group; founder of the Brain-Score benchmarking platform.

Co-founder of Neurosoft Bioelectronics. Its own team card also lists her as an EPFL full professor and Vice President for Support to Strategic Initiatives; those are external academic offices.

Listed on Neurosoft Bioelectronics’ combined Board & Advisors roster. Own card context: General Manager of Heraeus Materials. The directory does not distinguish a board appointment from an advisory appointment.

Avation Medical develops wearable peripheral-nerve stimulation and digital-health technology for bladder symptoms. Its prescription Vivally System combines an ankle-worn garment and stimulator with a mobile application to deliver non-invasive electrical stimulation of the tibial nerve at home. Electromyographic sensors measure nerve activation, and proprietary control software continuously adjusts stimulation within a clinician-calibrated therapeutic range. The system treats urge urinary incontinence and urinary urgency associated with overactive bladder, pairing stimulation with behavioral support and symptom tracking. The U.S. FDA cleared Vivally through the 510(k) pathway, K220454, on April3,2023. The current company is led by co-founder, CEO and board member Manish Vaishya.

Darren Wennen was appointed Avation Medical chief marketing officer in April2022, responsible for marketing, sales operations and customer care ahead of commercialization. The issuer describes earlier commercial and marketing leadership at Tactile Medical and other medical-device businesses. Current employment is unconfirmed.

Jason Whiting was appointed Avation Medical CEO in November2024. Its issuer biography describes more than 25 years in medical technology and eight years leading ZOLL Cardiac Management Solutions. Avation announced Manish Vaishya as CEO in March2026.

Manish Vaishya is Avation Medical’s co-founder, CEO and board member. He led the development of the Vivally wearable neuromodulation system through clinical trials, FDA 510(k) clearance and commercialization. The company publishes more than 25 years of medical-technology experience and a PhD in mechanical and systems engineering, MBA in international marketing, and BSc from IIT Kanpur.

Michael Hoffman was appointed Avation Medical vice president of market access and payer relations in April2024. Avestria’s own portfolio update describes his remit as reimbursement, payer coverage and commercial market-access strategy for Vivally. Current employment is unconfirmed.

Raymond Huggenberger was appointed an independent director of Avation Medical in December2021. Its release identifies him as a former president and CEO of Inogen and an industry adviser to Arboretum Ventures. Current board membership is not confirmed.

Renee Selman was appointed an independent director of Avation Medical in December2021. The issuer identifies her earlier role as Worldwide President of Women’s Health and Urology at Ethicon, a Johnson & Johnson business. Current board membership is not confirmed.

Susan L-J Dickinson is AFTD’s former chief executive officer, leading the charity from2008 until retirement in May2026. She is a genetic counselor with an Arcadia University master’s degree and Swarthmore biology/psychology undergraduate education. Her professional work supported communication among researchers, clinicians and the public, expansion of FTD research programmes and development of support services. A stale translated staff directory identifies her former role and authentic portrait; current English staff and Summer2026 leadership sources confirm Rachel Biblow succeeded her. The historical affiliation is not represented as current leadership.

CVX Ventures is a Nordic angel-investment and business-advisory community operated by Danish CVX Ventures ApS, company registration CVR41287772. Its own terms identify the legal operator at Sølvgade10,1307CopenhagenK; the about page also retains a different Copenhagen address, so location is recorded at city level. Founded in2020, CVX connects growth companies with experienced professional partners who contribute capital, networks and board/advisory expertise. Its membership terms distinguish facilitated partner investments from board appointments and direct company-to-partner compensation. CVX assists investment processes from introduction to signing; this does not establish that the operator itself supplies every disclosed investment or that a named employee invests personally. Primary gMendel disclosures explicitly identify CVX Ventures among Danish angel backers of2023 funding and link cvx.vc; this is qualified collective backing with underlying investor vehicle and individual allocation unpublished. Relevant opportunities span AI, genomics, biotechnology, robotics, semiconductors and autonomous systems. The public directory names11 current people across management, investment/advisory, partner relations, marketing and analysis. DKK800M described as available together with partners is investment capacity, not a completed LP fund close or verified operator deployment. Company-support counts combine investments and board work; portfolio logos, mentor cases and open funding pitches are not automatically equity investments. No separate legal LP fund or actual fund closing is established by the reviewed primary sources.

George Chapipis is publicly listed by CVX Ventures as Partner Relations. CVX is a Nordic investment and advisory community connecting growth companies with experienced investors, board members and advisers. This biography records the published professional affiliation; detailed education and earlier career are not established by the current team directory.

Jacob Søhoel is publicly listed by CVX Ventures as Investment & Advisory Manager. CVX is a Nordic investment and advisory community connecting growth companies with experienced investors, board members and advisers. This biography records the published professional affiliation; detailed education and earlier career are not established by the current team directory.

Kim Drud Abildgaard is publicly listed by CVX Ventures as Investment & Advisory Manager. CVX is a Nordic investment and advisory community connecting growth companies with experienced investors, board members and advisers. This biography records the published professional affiliation; detailed education and earlier career are not established by the current team directory.

Mathias Sønke Pedersen is publicly listed by CVX Ventures as Investment & Advisory Manager. CVX is a Nordic investment and advisory community connecting growth companies with experienced investors, board members and advisers. This biography records the published professional affiliation; detailed education and earlier career are not established by the current team directory.

Mikkel Graae Pedersen is publicly listed by CVX Ventures as Investment & Advisory Manager. CVX is a Nordic investment and advisory community connecting growth companies with experienced investors, board members and advisers. This biography records the published professional affiliation; detailed education and earlier career are not established by the current team directory.

Oscar Thybo heads Board & Investment at CVX Ventures; his separate own biography describes the Board & Advisory function. He matches companies with experienced partners and has a Copenhagen Business School business-economics background, including a semester in Singapore. He previously spent five years at Flyhjælp, managing a 22-person department and working on business development, partnerships, finance and a company sale. He hosts Vækstmaskinen and participates in startup pitch panels.

Shakib Ghaderi is publicly listed by CVX Ventures as Partner Relations. CVX is a Nordic investment and advisory community connecting growth companies with experienced investors, board members and advisers. This biography records the published professional affiliation; detailed education and earlier career are not established by the current team directory.

Stella Blicher is publicly listed by CVX Ventures as Marketing Associate. CVX is a Nordic investment and advisory community connecting growth companies with experienced investors, board members and advisers. This biography records the published professional affiliation; detailed education and earlier career are not established by the current team directory.

Steve Olesen is publicly listed by CVX Ventures as Partner Relations. CVX is a Nordic investment and advisory community connecting growth companies with experienced investors, board members and advisers. This biography records the published professional affiliation; detailed education and earlier career are not established by the current team directory.

Valdemar Langsager is publicly listed by CVX Ventures as Venture Analyst. CVX is a Nordic investment and advisory community connecting growth companies with experienced investors, board members and advisers. This biography records the published professional affiliation; detailed education and earlier career are not established by the current team directory.

Zenia W. Francker is publicly listed by CVX Ventures as Director. CVX is a Nordic investment and advisory community connecting growth companies with experienced investors, board members and advisers. This biography records the published professional affiliation; detailed education and earlier career are not established by the current team directory.

Willem-Jan Wollants is named Scientist – Droia Labs in Droia’s current public directory. The published professional background includes Bioengineer, KU Leuven; IBD research group, KU Leuven; Labmanager at Flamingo Therapeutics. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Evelien Verdrengh is named Office Manager & Executive Assistant in Droia’s current public directory. The directory does not publish a longer career biography. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Jens Van fraeyenhove is named Investment Analyst in Droia’s current public directory. The directory does not publish a longer career biography. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Nele Vandervoort is named Senior Scientist – Droia Labs in Droia’s current public directory. The published professional background includes M.Sc. Biomedical Sciences KU Leuven; Former senior scientist at Galapagos NV and Augustine Therapeutics. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Matthew Vander Heiden is named Investment Advisory Board in Droia’s current public directory. The published professional background includes Associate Professor in the Department of Biology at the Massachusetts Institute of Technology; Associate Director of the Koch Institute for Integrative Cancer Research; Institute Member of the Broad Institute of Harvard and MIT; Instructor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Nathan Tops is named Business Development Analyst in Droia’s current public directory. The published professional background includes Master in Biochemistry & Biotechnology - KU Leuven; Master in Management - INSEAD; Investment Fellow - Ackermans & van Haaren; Business Development intern - Engine Biosciences; Market Access intern - AxTalis. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Simona Talpau is named Accountant in Droia’s current public directory. The directory does not publish a longer career biography. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Joris Souffreau is named Senior Technician – Droia Labs in Droia’s current public directory. The published professional background includes M.Sc. Biology Ghent University; Labtechnician at Center for Cancer Biology (CCB), VIB, Leuven. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Kathleen Sonck is named Principal Scientist – Droia Labs in Droia’s current public directory. The published professional background includes M.sc. in Bioengineering (cel and gene biotechnology), KU Leuven; Ph.D. in Bioengineering, Centre of Microbial and Plant Genetics, KU Leuven; Former senior scientist at Galapagos NV and Aelin Therapeutics; (Antimicrobial, Cystic Fibrosis and lung fibrosis drug development experience). This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

A. Campbell Sullivan is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is University of Texas San Antonio. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Hendrik P.N. Scholl is named Investment Advisory Board in Droia’s current public directory. The published professional background includes M.D. University of Tübingen; Professor and Chairman of the Department of Ophthalmology, University of Basel; Founding and Scientific Director of the Institute of Molecular and Clinical Ophthalmology Basel (IOB); Retinal specialist with expertise in translational research in ophthalmology, especially gene therapy. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Emily Rogalski is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is Northwestern/University of Chicago. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Eric Rowinsky is named Investment Advisory Board in Droia’s current public directory. The published professional background includes Executive Chairman of RGenix, Inc; Board Member at Biogen, Navidea, Fortress Biotech, Verastem; Chief Medical Office/Scientific Advisor: Hummingbird Biosciences, Oncotartis, Lokon; Oncology Advisor, Everest Medicines. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Kristoffer Rhoads is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is University of Washington. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Sergio Quezada is named Investment Advisory Board in Droia’s current public directory. The published professional background includes Professor of Cancer Immunology and Immunotherapy at UCL Cancer Institute; Group Leader of the Immune Regulation and Tumour Immunotherapy Laboratory; CRUK Senior Cancer Research Fellow; Co-leading scientist CRUK Cancer Immunotherapy Accelerator; CSO at Achilles Therapeutics. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Kate Possin is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is University of California, San Francisco. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Magdalini Polymenidou is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is University of Zurich. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Sara Morren is named Chief of Staff to Managing Partner in Droia’s current public directory. The directory does not publish a longer career biography. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Olivier Piguet is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is University of Sydney. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Darby Morhardt is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is Northwestern University. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Mary O’Hara is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is University of Colorado. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Xin-An Lin is named VP Finance in Droia’s current public directory. The directory does not publish a longer career biography. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Guy Eelen is named VP R&D – Droia Labs in Droia’s current public directory. The published professional background includes PhD in Medical Sciences, KU Leuven; FWO postdoctoral fellow; Postgraduate Business Administration, KU Leuven; Former senior staff, Center for Cancer Biology (CCB), VIB, Leuven. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Lauren Massimo is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is University of Pennsylvania. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Leonard van den Berg is a QurAlis clinical adviser and motor-neuron disease researcher associated with Utrecht and the Dutch ALS centre. His training includes medical studies in Groningen, doctoral research at Utrecht and a fellowship at Columbia.

Alexander Depauw is named General Counsel in Droia’s current public directory. The published professional background includes Master of Laws, University of Ghent and University of Copenhagen; LL.M in International Financial Law, King’s College London; Lydian; De Cronos Groep. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Allison Lindauer is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is Oregon Health & Science University. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Dame Pamela Shaw is a QurAlis clinical adviser and neurological researcher at the University of Sheffield. Her work centres on motor-neuron disease and the Sheffield Institute for Translational Neuroscience.

Mathias De Decker is named Senior Associate in Droia’s current public directory. The published professional background includes PhD Biomedical Sciences, Molecular Neurosciences, University of Leuven; FWO Doctoral Research at Lab of Neurobiology (VIB), University of Leuven; M. Sc. Bioengineering, Cell and Gene Technology, University of Leuven; Internship at Biocartis. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Maya Lichtenstein is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is Geisinger Health. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Mathias Declercq is named Principal in Droia’s current public directory. The published professional background includes PhD Biomedical Sciences, University of Leuven; Doctoral Research at Angiogenesis and Vascular Metabolism lab (VIB) and Woman & Child unit, Cystic Fibrosis lab (KU Leuven/UZ Leuven); MSc Biochemistry-Biotechnology, University of Leuven; MSc Management, University of Leuven. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Tammaryn Lashley is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is University College London. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Celeste Karch is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is Washington University. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Nathalie De Blieck is named Director of Accounting in Droia’s current public directory. The directory does not publish a longer career biography. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Ammar Al-Chalabi is a QurAlis clinical adviser and King’s College London professor studying ALS genetics and clinical disease. His current university biography identifies leadership of its Motor Neuron Disease Care and Research Centre and co-direction of the UK MND Research Institute, with work on Project MinE and the UK MND register.

David Irwin is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is University of Pennsylvania. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Jo Bury is named Investment Advisory Board in Droia’s current public directory. The published professional background includes Master in pharmaceutical sciences, UGent; PhD Biochemistry, UGent; MBA, Vlerick School for management; Founder of VIB; Managing Director VIB 1995-2022; Non executive director of companies and research institutions. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Katleen Brepoels is named Senior Technician – Droia Labs in Droia’s current public directory. The published professional background includes Bachelor Pharmaceutical and Biological Techniques Ghent; Senior labtechnician at Center for Cancer Biology (CCB), VIB, Leuven. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Maya Henry is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is University of Texas Austin. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Brian Wainger, MD, PhD, is a QurAlis scientific adviser whose neurological research spans patient-derived cell models, ALS and pain. His training includes Princeton, Columbia and Massachusetts General Hospital, with research at Boston Children’s Hospital and Harvard.

Nupur Ghoshal is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is Washington University in St. Louis. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Sophie Bernier is named Compliance Manager in Droia’s current public directory. The directory does not publish a longer career biography. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Tania Gendron is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is University of Miami. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Bernhardt Trout is a QurAlis scientific adviser and MIT chemical-engineering professor. His research combines pharmaceutical manufacturing, physical chemistry and computational methods; he trained at MIT and Berkeley and undertook postdoctoral work at the Max Planck Institute.

Fen-Biao Gao is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is University of Massachusetts. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Jamie Fong is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is Baylor University. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Mark S. Forman is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is Ventyx Biosciences. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Roderick Beijersbergen is named Investment Advisory Board in Droia’s current public directory. The published professional background includes Group leader at the Netherlands Cancer Institute; Head of the NKI Robotics and Screening Center; Expert in large scale functional genomics; Pioneer of pooled screening technology; Co-founder of Qameleon Therapeutics. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Sebastian Bernales is named Venture Partner in Droia’s current public directory. The published professional background includes BA in Biochemistry, Catholic University in Chile; PhD in Cell Biology, UCSF; Medivation; Praxis Biotech; Merken Biotech. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Tirtha Chakraborty is named Venture Partner in Droia’s current public directory. The published professional background includes Ph.D. in Molecular Biology from TIFR, Mumbai, India; Trained at Yale, NIH and Harvard in RNA metabolism, genetic engineering and immunology; mRNA platform lead, Moderna Therapeutics; Head of Hematology, CRISPR Therapeutics; VP of Cell Therapy, Sana Biotechnology; CSO and Head of Tech Ops, Vor Bio; SAB member at Specific Biologics. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Christopher Shaw is a QurAlis scientific adviser and neurologist at King’s College London studying ALS genetics. His research includes disease-associated TARDBP and FUS mechanisms, following doctoral training at Cambridge; he is distinct from the real-estate professional of the same name already in Adex.

George Golumbeski is named Partner in Droia’s current public directory. The published professional background includes BA in Biology, University of Virginia; PhD in Genetics, University of Wisconsin-Madison; Novartis; Celgene (Bristol Myers Squibb); Arch Venture Partners; Board member Acceleron Pharma, Sage Therapeutics, Carrick Therapeutics, Shattuck Labs and others. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Howard Feldman is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is University of California, San Diego. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Matthias Van Woensel is named Partner in Droia’s current public directory. The published professional background includes M. Sc. Biomedical Sciences, University of Leuven; PhD Biomedical Sciences – Tumor Immunology, University of Leuven; PhD Pharmaceutical Sciences – Polymers, ULB; PhD fellow IWT; Recipient VCU RDD Peter R. Byron Graduate Student Award; Belgian Brain Tumor Support. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Dennis Dickson is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is Mayo Clinic Florida. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Fayron Epps is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is Emory University. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Luc Verelst is named Founder & Chairman in Droia’s current public directory. The published professional background includes M.Sc. Bio-Engineering, University of Leuven; Founder / former owner of Verelst real estate group; Seasoned investor in small and big biotech, venture capital; Founder of the Anti Cancer Fund and the Verelst Uterine Cancer Fund. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Janwillem Naesens is named Managing Partner Oncology & Droia Group in Droia’s current public directory. The published professional background includes M.Sc. Engineering, University of Leuven; MBA, INSEAD; McKinsey & Company; Waterland Private Equity. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Kevin Eggan, PhD, co-founded QurAlis and serves on its scientific advisory board. He is a stem-cell and neurodegeneration researcher whose career includes Harvard and the Broad Institute and later BioMarin research leadership; he trained at the University of Illinois, MIT and the Whitehead Institute.

Richard Ryan Darby is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its education committee. Its published professional affiliation is Vanderbilt University. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Droia Ventures is a specialist biotechnology investment and company-building group focused on therapeutics for oncology and genetic diseases. It invests globally in young drug developers and uses in-house biology, translational research and clinical-development experience to help companies progress toward clinical proof of concept. Its public legal/contact footer distinguishes Droia SA in Luxembourg, the Belgian Droia Ventures office in Zaventem, and Metaptys NV / Droia Labs in Leuven. Droia Labs is the group’s scientific validation arm rather than a separately attributed financing buyer. Current own portfolio exposure includes ALS precision medicines at QurAlis, neurodegeneration at Muna Therapeutics, rare genetic neurodevelopmental conditions at Mahzi, neuroinflammation at Montis and neuroscience-related kinase programmes at Alesta. These are development mandates rather than proven clinical outcomes. The public directory lists33 investment, operating, laboratory and advisory people with their functions explicitly scoped. Its own final-close announcements verify EUR150M for the second oncology fund in December2018 and EUR220M for Droia Genetic Disease, the third fund, in May2021. Droia I is established by the second-fund announcement but its cash size and exact close date are undisclosed. The older Droia Oncology Ventures / droiagroup.com brand is linked by the group’s own fund history; separate managed funds retain their identities. AUM figures are not additional fundraise events. Founding-year sources differ (company socialprofile2011 versus regionalagency2014), so a single legal-founding year is not asserted.

Jalayne J. Arias is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is Georgia State University. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Sami Barmada is listed by AFTD as External Medical Advisory Council Member. The directory assigns this external adviser to its research & grants committee. Its published professional affiliation is University of Michigan. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred. Sami Barmada is listed among Synapticure’s scientific and strategic advisers. The issuer publishes the professional affiliation Director, Michigan Brain Bank and Neurology Associate Professor at University of Michigan Medical School. This outside title is retained as a source-qualified professional description rather than Synapticure operating employment. Additional career details and dates are not disclosed in this directory.

Sudhir Agrawal is a scientific adviser to QurAlis and a specialist in antisense and nucleic-acid therapeutics. His work includes founding Idera and Arnay Therapeutics and academic collaboration with the University of Massachusetts Medical School.

Howard Rosen is listed by AFTD as External Medical Advisory Council Member; Education Committee Chair. Its published professional affiliation is University of California, San Francisco. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Carmela Tartaglia is listed by AFTD as External Medical Advisory Council Chair Elect. Its published professional affiliation is University of Toronto. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

John Sims, MD, is a QurAlis director affiliated with Eli Lilly. His career combines neurological clinical research with drug-development leadership, including Lilly work on donanemab, prior Harvard/Massachusetts General Hospital research and a Dartmouth medical degree.

Chiadi Onyike is listed by AFTD as External Medical Advisory Council Chair (2025–2028). Its published professional affiliation is Johns Hopkins University. This is source-published advisory context; additional employer roles, a clinical approval and personal investment are not inferred.

Helen-Ann Comstock is publicly listed by AFTD as Founder; Historical Board Member (2002–2025). She founded AFTD in2002 and previously directed the Southeastern Chapter of the Alzheimer’s Association. She served on the AFTD board from2002 until her death on July30,2025; her founder and board affiliation is explicitly historical.

Abrar Tanveer is publicly listed by AFTD as Board Member. His published professional background includes health-technology startups following Ohio State graduation2017 and a Venture for America fellowship2018.

Anne Clem Whitaker chairs the QurAlis board. She has held senior commercial and executive roles at Sanofi, GlaxoSmithKline, Bausch Health and Aerami Therapeutics, and studied chemistry at the University of North Alabama.

Kristin Schneeman is publicly listed by AFTD as Board Member. She directs innovation work at FasterCures, part of the Milken Institute, focusing on research funding, collaboration and translation of treatments.

Margaret Sutherland is publicly listed by AFTD as Board Member. Her professional biography identifies a Chan Zuckerberg Initiative Neurodegeneration Challenge Network programme-management role, earlier NINDS programme leadership2007–2019, and academic pharmacology posts. She earned a Cambridge molecular-biology PhD and trained at Baylor.

David Pfeifer is publicly listed by AFTD as Board Member. He is president of Anderson Mason Dale Architects and a University of Cincinnati design, architecture, art and planning graduate.

Girish Patangay is publicly listed by AFTD as Board Member. He leads Chan Zuckerberg Initiative central technology teams supporting science and education. His previous decade at Meta involved infrastructure, developer tools and AR/VR products; AFTD also identifies prior technical advice to the FTD Disorders Registry.

Manoj Malhotra, MD, is chief medical officer of QurAlis. Previously a neuroscience and eye-care medical-affairs leader at AbbVie and CMO at Ovid Therapeutics, he trained at Wayne State University and the Cleveland Clinic and has clinical and development experience across neurological and rare diseases.

Vikas Sharma, PhD, leads business development as chief business officer of QurAlis. His prior roles include BioXcel Therapeutics, MacroGenics, Rexahn and MedImmune/AstraZeneca; he trained in immunology at Rutgers and microbiology in Mumbai.

Kathy Newhouse Mele is publicly listed by AFTD as Board Member. Her professional experience includes elementary and English-as-a-second-language teaching and chairing the Angel Shine Foundation for dance education.

Daniel (Dan) Elbaum, PhD, is chief scientific officer of QurAlis, with experience in medicinal chemistry and rare-disease drug discovery. His career includes Pfizer, Amgen, Kinetix, FoldRx and Retrophin, following Harvard chemistry training and postdoctoral work at the University of Pennsylvania.

Guzide Adhikari leads CMC operations and strategy at QurAlis, which she joined in2021. Her published biography describes global clinical supply and operational roles at Translate Bio and Takeda/Shire, industrial-engineering training at Dokuz Eylul University and graduate operations-research studies at Northeastern.

Hagen Cramer, PhD, is chief technology officer of QurAlis and an oligonucleotide chemistry and manufacturing specialist. His prior work includes Wave Life Sciences, Girindus and Nitto Denko Avecia, following chemistry doctoral training at Konstanz and postdoctoral research at the NIH.

Jary Larsen is publicly listed by AFTD as Board Member. He is a licensed neuropsychologist affiliated in the published biography with UCSF/ZSFG and the VA Northern California Cognitive Neuropsychology and Electrophysiology laboratory. His earlier AFTD board2010–2017 and chair2013–2016 service is historical.

Jason Brown is CFO and COO of QurAlis. He previously led finance at Karuna Therapeutics and held financial responsibilities at PureTech Health and Novartis; he holds a Hamilton College degree and a Boston College MBA.

Joseph Marquez is publicly listed by AFTD as Board Member. He is a Seattle urologist and multispecialty-practice department founder. He studied at UC Santa Cruz and Northwestern medicine, with residency training at Minnesota.

Shoshana Derrow Krilow is publicly listed by AFTD as Board Member. Her professional biography includes Vizient public-policy and government-relations leadership, University of California federal health affairs, congressional health policy and financial-services experience.

Joe Esposito is publicly listed by AFTD as Board Member. AFTD identifies him as a Jennison managing director and portfolio manager since2014, previously at Loomis Sayles and AXA. His education includes The College of New Jersey and Columbia MBA; he is a CFA charterholder.

Kasper Roet, PhD, is a co-founder and CEO of QurAlis, developing precision therapies for ALS and related neurodegeneration. He also co-founded EnClear Therapies and trained in neurobiology at the Netherlands Institute for Neuroscience, VU Amsterdam and Harvard; his research combines patient-derived stem-cell models with therapeutic target discovery.

Kimberly Radford Henderson is publicly listed by AFTD as Board Member. Her published career includes Meta global content marketing, Johnson & Johnson and Unilever brand strategy. She studied at Wake Forest and Duke’s Fuqua School.

Gail Andersen is publicly listed by AFTD as Board Member. She retired after a thirty-one-year Procter & Gamble career including innovation leadership. Her AFTD chairmanship during2016–2020 is historical.

Halima Amjad is publicly listed by AFTD as Board Member. She is a Johns Hopkins geriatrician and dementia-care researcher, with medical education at Drexel, residency at Yale and fellowship training at Johns Hopkins.

Kyle Birmingham is publicly listed by AFTD as Board Member at Large. He is a portfolio manager at Quorus with prior financial-technology and Vanguard investment-strategy experience.

Julie Kelly is publicly listed by AFTD as Board Treasurer. Her published background includes managing director and private-client adviser at Logan Capital since2009, with previous BNY Mellon, Summit and ANB work and Indiana Kelley business education.

Valerie L. Snow is publicly listed by AFTD as Board Recording Secretary. She is a nonprofit lawyer whose professional practice supports access to disability services and representation in guardianship matters.

Leonard Marquez is publicly listed by AFTD as Board Vice Chair. His professional biography identifies AAMC government relations and legislative advocacy leadership, with previous roles at Cleveland Clinic, MetroHealth and in congressional service. He studied at Xavier and American University.

Rita B. Choula is publicly listed by AFTD as Board Chair. AFTD identifies her as AARP senior director for caregiving, connecting policy and practice.

Ashlyn Stienstra is publicly listed by AFTD as Fundraising Coordinator. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Elizabeth R. Young is publicly listed by AFTD as Executive Assistant/Board Liaison. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Ann Schoonover is publicly listed by AFTD as HelpLine Specialist. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Cameron Reid is publicly listed by AFTD as Development Writer. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Wendy Rollins is publicly listed by AFTD as Events Coordinator. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Eva Morrison is publicly listed by AFTD as Social Media Coordinator. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Lauren Pelaia is publicly listed by AFTD as Advocacy Coordinator. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Mike Mooney is publicly listed by AFTD as Marketing Cloud Coordinator. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Michael Mignone is publicly listed by AFTD as Education Coordinator. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Evelyn Lewis is publicly listed by AFTD as Volunteer Engagement Coordinator. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Olivia Klenn is publicly listed by AFTD as Administrative Assistant, Support and Education. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Hannah Gruen is publicly listed by AFTD as Volunteer Engagement Coordinator. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Samantha Garner is publicly listed by AFTD as Research Coordinator. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Hailey Fleischmann is publicly listed by AFTD as HelpLine Advisor. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Alyssa Fikaris is publicly listed by AFTD as HelpLine Advisor. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Erin Ficca is publicly listed by AFTD as Support Services Specialist. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Jeni Cardosi is publicly listed by AFTD as Human Resources Specialist. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Hilary Boucher is publicly listed by AFTD as Support Services Coordinator. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Yue Zhang is publicly listed by AFTD as Senior Accountant. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Jeff Thompson is publicly listed by AFTD as Operations Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Kate Still is publicly listed by AFTD as Research Outreach Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Sandy Sosa is publicly listed by AFTD as Social Media Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

QurAlis Corporation is a Cambridge, Massachusetts biotechnology company developing precision medicines for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and other neurodegenerative diseases. Its research combines disease genetics, patient-derived stem-cell models and biomarkers with small-molecule and antisense oligonucleotide therapies. Its FlexASO platform develops splice-modulating antisense compounds; clinical programmes include QRL-201 and QRL-101. The company is relevant to neuroscience and advanced biotechnology; no unsupported artificial-intelligence claim is made. The current own team page, modified September9,2026, publishes seven executives, nine board members, eight scientific advisers and five clinical advisers, representing28 distinct people. Kasper Roet serves as CEO and board member; Kevin Eggan and Clifford Woolf also have explicit founder affiliations. An obsolete hidden Jinsy Andrews modal is not treated as current roster membership. Manoj Malhotra is the current CMO, superseding older Doug Williamson announcements. One published adviser modal incorrectly reuses Manoj’s photo; Ammar Al-Chalabi’s authentic original portrait is instead verified against his own King’s College London biography. Shared people’s biographies, portraits and external affiliations are preserved. Primary financing includes an undisclosed-size seed round reported April5,2018, USD42million SeriesA announced May13,2020, and USD88million SeriesB closed March9,2023. Cumulative totals are not additional rounds. A June3,2024 Lilly agreement combines an upfront USD45million licensing payment with a separately stated equity investment of undisclosed amount; the licensing payment and potential USD577million future milestones are not equity fundraising. ALS Association research awards are recorded separately from private investment. The2017 Amgen Golden Ticket provided laboratory space and services, not an inferred cash financing. SEC filings identify the Delaware corporation, incorporated in2016 (CIK1811817). Separate convertible-promissory-note offerings reported USD5million securities sold in2022 and USD19,952,387 in2025; their targets of USD10million and USD24,921,734 are not completed raises. The cash fields remain unquantified pending reconciliation of note conversions with later equity financing. SeriesA andB SEC snapshots describe those same offerings and are not extra rounds. The March2026 corporate presentation explicitly described SeriesC funding as pending.

Omair Siddiqui is publicly listed by AFTD as Digital Marketing Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Jillian Shellenberger is publicly listed by AFTD as Events Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Matthew Sharp is publicly listed by AFTD as Federal Advocacy Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Stephanie Quigley is publicly listed by AFTD as HelpLine Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Michael Mullan is publicly listed by AFTD as Volunteer Services Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Sarah Lopata is publicly listed by AFTD as Support Services Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Elizabeth Graham is publicly listed by AFTD as Corporate and Foundation Relations Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Kim Jenny is publicly listed by AFTD as Manager of Genetic Initiatives. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Amanda Gleixner is publicly listed by AFTD as Research Projects Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Danielle Gershkoff is publicly listed by AFTD as Donor Engagement Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Jeanne Cestone is publicly listed by AFTD as Healthcare Education Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Jenny Catchings is publicly listed by AFTD as State Advocacy Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Abby Addvensky is publicly listed by AFTD as Annual Giving Manager. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Peter Witzleb is publicly listed by AFTD as Director of IT. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Michelle Thompson is publicly listed by AFTD as Director of Finance. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

PJ Lepp is publicly listed by AFTD as Director of Marketing & Communications. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Amanda Knight is publicly listed by AFTD as Director of Development. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Esther Kane is publicly listed by AFTD as Support & Education Director. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Marsha Jackson is publicly listed by AFTD as Director of Fundraising Events. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Bridget Graham is publicly listed by AFTD as Director of Meetings & Conferences. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Shana Dodge is publicly listed by AFTD as Director of Research Engagement. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Meghan Buzby is publicly listed by AFTD as Director of Advocacy and Volunteer Engagement. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Cynthia Brown-Smith is publicly listed by AFTD as Director of Human Resources. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Nicole Bjorklund is publicly listed by AFTD as Director of Research & Grants. The own published directory provides this professional affiliation, without a full prior-career biography or precise appointment day.

Phillip Weichel is publicly listed by AFTD as Vice President of Advancement. He became vice president in January2024 after leadership work at the Leukemia & Lymphoma Society, Cystic Fibrosis Foundation, Crohn’s and Colitis Foundation and Arthritis Foundation. He holds a Boston University MSW.

Sharon S. Denny is publicly listed by AFTD as Vice President of Mission Services. She joined AFTD in September2008 and leads support, education and advocacy. She holds clinical psychology qualifications from West Chester and psychology training from Holy Cross.

Penny Dacks is publicly listed by AFTD as Chief Scientific Officer. She joined AFTD in September2020 after scientific-programme roles at the American Epilepsy Society and Alzheimer’s Drug Discovery Foundation. She earned a neuroscience PhD at Arizona and leads AFTD research strategy; its directory also identifies her as president of the FTD Disorders Registry.

Mitch Appleson is publicly listed by AFTD as Chief Operating Officer. A CPA with an accounting degree from Yeshiva University and MBA from Saint Joseph’s, he joined AFTD in March2022 after serving as CFO of Alliance Cancer Specialists. His earlier healthcare and research administration roles included Columbia, CHOP, Penn and Drexel.

Rachel Biblow is publicly listed by AFTD as Chief Executive Officer. She previously led the Outcomes Institute, worked on transformation at Press Ganey and ChenMed, and spent more than fifteen years at Children’s Hospital of Philadelphia.

The Association for Frontotemporal Degeneration (AFTD) is a US nonprofit public charity founded in2002 by Helen-Ann Comstock to support people affected by frontotemporal degeneration and advance research towards treatments and a cure. Its official tax return identifies EIN41-2073220, Pennsylvania organization, and Section501(c)(3) status. It is headquartered at2700 Horizon Drive, Suite120, King of Prussia, Pennsylvania19406. This is a neuroscience research and mission-related investment institution, rather than a commercial venture manager. AFTD's work combines scientific funding, research participation and engagement, medical education, support services and public advocacy. Its scientific interests span FTD biology, genetics, biomarkers, clinical studies and development of disease-modifying therapies. Its current scientific leadership includes Chief Scientific Officer Penny Dacks. Rachel Biblow became CEO in May2026, succeeding Susan L-J Dickinson; older documents naming Susan as CEO are historical. The current public professional directories publish51 staff,18 current directors and31 active external Medical Advisory Council members. External advisers are scoped advisory relationships rather than employees. Founder Helen-Ann Comstock's board service ended with her death on July30,2025. AFTD and the Alzheimer's Drug Discovery Foundation jointly established the Treat FTD programme in2016. Its current call supports relevant clinical trials through academic grants or biotechnology mission-related investments. Award ceilings, charitable income, programme budgets and fundraising goals are not LP fund closes or evidence of cash already paid. Biotechnology payments may depend on negotiated development and enrollment milestones. Treat FTD is recorded as a joint programme of its two institutions rather than a third duplicate cash investor. Vesper Bio announced a USD2.5million strategic mission-related investment from AFTD and ADDF through Treat FTD on November17,2025. Per-institution allocations and actual disbursement schedule are undisclosed. This funding relationship does not establish regulatory approval or proven clinical benefit of Vesper's investigational medicine. Exact company financing is source-qualified on the issuer record and is maintained separately from AFTD's charitable receipts. No commercial investment-fund ownership or institution-wide health status is inferred from its mission.